Jeffrey Hnath, MD
Vascular Surgery · Albany, NYNPI 1326206640
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $203,061 of the $289,027 with a category attached, or 70.3%. Medtronic accounts for 78.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $71,379 and has fallen 55.4% since, to $31,821 in 2025. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,179 payments — averaging $245.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$228K
- Boston Scientific$40K
- W. L. Gore & Associates, Inc.$17K
- Inari Medical, Inc.$2K
- Lemaitre Vascular, Inc.$842
- Philips North America LLC$419
- plus $1K from 13 others
Across 71 payments — averaging $1591.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$108K
- Inari Medical, Inc.$5K
What the payments were for
- Consulting fees$26,0639%
- Speaking & faculty fees$203,06170%
- Grants$2000%
- Travel & lodging$30,59411%
- Food & beverage$29,00110%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 762 | $227,655 |
| Boston Scientific | 251 | $40,083 |
| W. L. Gore & Associates, Inc. | 97 | $16,731 |
| Inari Medical, Inc. | 21 | $2,169 |
| Lemaitre Vascular, Inc. | 14 | $842 |
| Philips North America LLC | 8 | $419 |
| Bard Peripheral Vascular, Inc. | 8 | $259 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $172 |
| Stryker | 1 | $167 |
| Penumbra, Inc. | 2 | $123 |
| Convatec Inc. | 1 | $102 |
| Abbott | 4 | $92 |
| Terumo Medical Corporation | 3 | $51 |
| Johnson & Johnson | 1 | $46 |
| Bolton Medical Inc | 1 | $30 |
| Reflow Medical Inc | 1 | $23 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $22 |
| Cvrx, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Valiant Captivia$118,056
- ENDURANT IIS$25,144
- Endurant$17,334
- IN.PACT Admiral$12,268
- Abre$10,310
- GORE VIABAHN VBX Balloon Expandable Endo$10,188
- Valiant Navion$10,000
- HawkOne$9,095
- ELUVIA$8,504
- GENERAL - THERAPIES$6,873
- GORE VIABAHN Endoprosthesis$6,786
- Ranger$4,000
- GENERAL VASCULAR INTERVENTION$3,809
- Heli-FX EndoAnchor System$3,349
- CT THROMBECTOMY SYSTEM KIT$3,319
- COREVALVE EVOLUT R$2,720
- SilverHawk$2,435
- VIABAHN VBX Balloon Expandable Endoprosthesis$2,227
- TurboHawk$1,781
- GORE TAG Thoracic Endoprosthesis$1,681
How this compares
$289,027 in reported general payments places this provider in the 95th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $57,520 |
| XareltoRivaroxaban | 31 | $25,756 |
| ClopidogrelClopidogrel Bisulfate | 116 | $1,136 |
| Cilostazol | 20 | $309 |
| Oxycodone Hcl | 30 | $164 |
| Prednisone | 20 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $46 | $25,75631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in Albany
- Kathleen OzsvathAlbany$183K
- Paul KreienbergAlbany$115K
- Yaron SternbachAlbany$40K
- Gary GelbfishNew York$1.9M
- Sundaram RavikumarDobbs Ferry$1.8M
- Antonios GasparisHuntington$1.5M
- Sonya NoorBuffalo$991K
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.